# A Safety Study of CC-92252 in Healthy Adult Subjects and Adult Subjects With Psoriasis

> **NCT03971825** · PHASE1 · TERMINATED · sponsor: **Celgene** · enrollment: 131 (actual)

## Conditions studied

- Healthy Volunteers
- Psoriasis

## Interventions

- **DRUG:** CC-92252
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03971825
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-24
- **Primary completion:** 2021-08-05
- **Final completion:** 2021-08-05
- **Target enrollment:** 131 (ACTUAL)
- **Why stopped:** Did not meet progression criteria
- **Last updated:** 2021-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03971825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03971825, "A Safety Study of CC-92252 in Healthy Adult Subjects and Adult Subjects With Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03971825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*